Company Monitoring Page for Genentech

latest headlines for company on cafepharma

BioNTech, Roche's experimental pancreatic cancer treatment wins Nature plaudit
Yahoo/Reuters
Thu, 05/11/23 - 10:08 am
Tags:
BioNTech, Roche, Genentech, pancreatic cancer, MRNA, Nature, vaccines
FDA Accepts Application for Genentech’s Vabysmo for the Treatment of Retinal Vein Occlusion (RVO)
BioSpace
Tue, 05/9/23 - 12:27 pm
Tags:
Roche, Genentech, FDA, Vabysmo, macular edema, retinal vein occlusion
Drugmakers take sides in Amgen, Regeneron fight over antibody patents
BioPharma Dive
Mon, 04/24/23 - 10:17 am
Tags:
Amgen, Regeneron Pharmaceuticals, Sanofi, Supreme Court, patents, Pfizer, Bayer, Roche, Genentech, AstraZeneca, JNJ
Genentech opens up eye patients’ world with Vabysmo
Medical Marketing and Media
Thu, 04/20/23 - 11:40 pm
Tags:
Genentech, Vabysmo, wet age-related macular degeneration, DTC ads
FDA Green Lights Roche's Polivy in First-Line DLBCL
BioSpace
Thu, 04/20/23 - 10:45 am
Tags:
Roche, Genentech, Polivy, diffuse large B-cell lymphoma, FDA
Genentech reveals positive results from cancer combo therapy trial
Clinical Trials Arena
Mon, 04/17/23 - 11:24 am
Tags:
Genentech, Tecentriq, Avastin, liver cancer, hepatocellular carcinoma
Top biotech licensing deals of Q1 2023
BioSpace
Thu, 03/30/23 - 11:03 am
Tags:
biotech, licensing, Moderna Therapeutics, CytomX, Voyager Therapeutics, Neurocrine Biosciences, Kronos Bio, Genentech, Karuna Therapeutics, Goldfinch Bio
Genentech turns out lights at first commercial biologics plant, laying off 265 staffers
Fierce Pharma
Thu, 03/23/23 - 09:10 pm
Tags:
Genentech, Roche, biologics, San Francisco, California, layoffs
At EpiBiologics, a pair of Genentech alumni wants to make next-gen protein degraders
BioPharma Dive
Wed, 03/22/23 - 10:07 am
Tags:
Genentech, EpiBiologics, protein degradation
FDA advisers question efficacy of Roche’s Polivy in first line LBCL
BioSpace
Wed, 03/8/23 - 11:30 am
Tags:
Roche, Genentech, Polivy, LBCL, large B-cell lymphoma
Roche sues Biogen over royalties related to multiple sclerosis drug Tysabri
Fierce Pharma
Wed, 03/1/23 - 07:08 pm
Tags:
Roche, Genentech, patents, MS, multiple sclerosis, legal, Tysabri
Genentech's California biologics facility will support launches in cancer, neuroscience and more: exec
Fierce Pharma
Tue, 02/21/23 - 04:46 pm
Tags:
Genentech, California, Roche, biologics, drug manufacturing
Genentech to start construction on a new manufacturing facility in California
Endpoints
Sun, 02/12/23 - 07:40 pm
Tags:
Genentech, Roche, drug manufacturing, California
Roche offers up to $554M in biobucks to in-need Kronos for small-molecule discovery pact
Fierce Biotech
Mon, 01/9/23 - 10:39 am
Tags:
Kronos Bio, biobucks, AML, Roche, Genentech, small molecule drugs, drug discovery
Roche further taps drug discovery spinout's Nimble tech in $1.1B biobucks deal
Fierce Biotech
Fri, 01/6/23 - 09:33 am
Tags:
Roche, Genentech, Nimble Therapeutics, biobucks, drug discovery
Genentech makes a flurry of marketing leadership hires
Medical Marketing and Media
Thu, 01/5/23 - 10:07 am
Tags:
Genentech, marketing, digital marketing
Roche Withdraws Tecentric for Bladder Cancer Indication
BioSpace
Tue, 11/29/22 - 11:06 am
Tags:
Roche, Genentech, bladder cancer, metastatic bladder cancer, Tecentriq
Genentech starts phase 2 trial to optimize delivery of eye disease cell therapy
Fierce Pharma
Mon, 11/28/22 - 07:41 pm
Tags:
Genentech, geographic atrophy, clinical trials, OpRegen, cell therapy
Best Places to Work in Biopharma 2023 Report Reveals Most Sought-After Employers
BioSpace
Mon, 11/14/22 - 10:59 am
Tags:
biotech, biopharma, employers, corporate culture, Moderna Therapeutics, Genentech, Pfizer, Amgen, AbbVie
Roche’s Ocrevus Shines in Relapsing-Remitting MS, Safety Studies
BioSpace
Thu, 11/3/22 - 07:28 pm
Tags:
Genentech, Roche, Ocrevus, MS, Relapsing Remitting Multiple Sclerosis

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.